RxDoctor Payments Data

Jonathan Schneider, MD

Gastroenterology · Nashville, TNNPI 1801943600

Payments from drug & device makers

$12,427in general payments, 2019–2025

Across 445 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endogastric Solutions, Inc$3K
  • AbbVie$3K
  • Kerecis Limited$1K
  • Conmed Corporation$677
  • Medtronic$596
  • Johnson & Johnson$557
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$1,75014%
  • Speaking & faculty fees$1501%
  • Travel & lodging$1,0128%
  • Food & beverage$9,50877%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,427 in reported general payments places this provider in the 75th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$125,388
Medicare patients
453
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide52$32,814
TrulancePlecanatide15$10,284
Balsalazide Disodium14$2,166
Ondansetron Hcl34$1,796
Omeprazole75$1,324
Esomeprazole Magnesium27$1,171
Budesonide DrBudesonide11$1,103
Sucralfate11$1,063
Pantoprazole Sodium46$654
Ondansetron OdtOndansetron21$574
CholestyramineCholestyramine (With Sugar)11$494
EnuloseLactulose13$387
Spironolactone11$289
Famotidine23$285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,927$32,81452 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$356$10,28415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →